Analyst Group Comment on STENOCARE Shifting Strategy to Focus on Trading and Exit from Production

STENOCARE announced on November 26th the STENOCARE 3.0 Strategy, which means that the company will focus on trading prescription-based medical cannabis sourced from suppliers and exit the production activities at STENOCARE’s own indoor cultivation facility. The decision is based on prolonged and uncertain approval timelines with the Danish Medicines Agency, which creates difficulties in establishing a reliable timeline for the facility's approval. This exit will eliminate approximately DKK 18m in cost obligations over the next six years.

Länk till analysen i sin helhet: https://analystgroup.se/kommentarer/comment-on-stenocare-shifting-strategy-to-focus-on-trading-and-exit-from-production/